Antitumor immune redirection using novel virus-inspired particles (vips) for uveal melanoma treatment
Active Project Grant Awarded Last action
- Award ID
- HT94252510358
- Recipient
-
Verimmune Inc. UEI FSFJQCTT4X78
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $470,362
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 92% complete
- Place of performance
- Washington, DC 20012, USA
Award details come from USAspending.gov.
About this award
The U.S. Defense Health Agency awarded a $470,362 Project Grant to Verimmune Inc. under the Military Medical Research and Development program (CFDA 12.420) to fund research on "ANTITUMOR IMMUNE REDIRECTION USING NOVEL VIRUS-INSPIRED PARTICLES (VIPS) FOR UVEAL MELANOMA TREATMENT". The project aims to develop novel virus-inspired particle (VIP) therapies to redirect the immune system to treat uveal melanoma, a rare and aggressive form of eye cancer. The award provides funding from June 1, 2025 through the ultimate completion date of November 30, 2026. The Military Medical Research and Development program supports advanced biomedical research to transform healthcare for military service members, veterans, and the broader public, with a focus on developing innovative diagnostic tools, therapeutic interventions, and clinical practices relevant to military health challenges.
Quick answers
Who received award HT94252510358?
HT94252510358 was awarded to Verimmune Inc. by Defense Health Agency (Department of Defense) on June 1, 2025.
How much is award HT94252510358 worth?
$470,362 has been obligated on HT94252510358.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award